これも、立憲が政権与党で自民党が野党だったら、普通に立憲がPfizer、Modernaを輸入し、恐らく自民党が「他の国のワクチンも検討しろ!」と言っていましたよ。与党、野党ってそういうものです。まあこの方は要するに野党の立憲民主党… https://t.co/jI6wwIQldO
※0518 P1成功を追記 COVID-19の治療薬として、ギリアドのレムデシビルが米国にて緊急承認されましたね。 解析前の主要評価項目の変更等議論が残るところではありますが、ひとまず治療薬の開発が一歩前に進んでよかったです。 日本における特例承認はちょっと雑すぎると思いますけど。 さて、治療薬は光明が見えましたが、ワクチンのほうの開発はどうでしょうか。 日本でも「お騒がせバイオ」のアンジェスを中心として、様々な企業が開発に取り組んでおりますが、今日はアメリカのモデルナ(Moderna)が開発している「mRNAワクチン」について、基本的なところを見ていきたいと思います。 参考として用いた資料は医薬品医療機器レギュラトリーサイエンスにて発出された「mRNA 医薬開発の世界的動向」です。 面白い資料なので、未読の方はご一読されることをお勧めします。 mRNAとは? mRNAとはメッセンジャー
新型コロナウイルスワクチンの「mRNA-1273」を開発したアメリカのバイオテクノロジー企業・Modernaが、新たに後天性免疫不全症候群(エイズ)を引き起こすヒト免疫不全ウイルス(HIV)や季節性インフルエンザ、ニパウイルスなどのワクチンを開発するとの計画を発表しました。新たに開発されるワクチンは新型コロナウイルスワクチンと同様にmRNAワクチンであるとのことです。 Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines | Moderna, Inc. https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-busin
各国で新型コロナウイルスワクチンの接種が始まり、日本にも2021年2月12日に最初のワクチンが到着しました。ところが、各メーカーはワクチンの量産に課題を抱えているとのことで、当初の予定通りにワクチンが供給されていないという問題も報じられています。そんな中、アメリカのバイオテクノロジー企業・Modernaが開発したワクチン「mRNA-1273」は、第2相臨床試験の結果から「完全な投与量の半分で十分な免疫を獲得できるかもしれない」と指摘されています。 A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine - ScienceDirect https://www.sciencedirect.com/s
Pfizer-BioNTech and Moderna doses ready for patients at Cornerstone Pharmacy in Little Rock, Ark., in March.Credit...Rory Doyle for The New York Times It was a constant refrain from federal health officials after the coronavirus vaccines were authorized: These shots are all equally effective. That has turned out not to be true. Roughly 221 million doses of the Pfizer-BioNTech vaccine have been dis
The vaccines made by Pfizer-BioNTech and Moderna set off a persistent immune reaction in the body that may protect against the coronavirus for years, scientists reported on Monday. The findings add to growing evidence that most people immunized with the mRNA vaccines may not need boosters, so long as the virus and its variants do not evolve much beyond their current forms — which is not guaranteed
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study First interim analysis included 95 participants with confirmed cases of COVID-19 Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% (p <0.0001) Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and e
Moderna COVID-19 Vaccine, Bivalent has not been approved or licensed by the FDA, but has been authorized by the FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19). Moderna COVID-19 Vaccine, Bivalent is authorized for use in individuals 6 months through 5 years of age who were previously unvaccinated or vaccinated with one or two doses of Moderna COVID-19
Vials of the Pfizer-BioNTech vaccine are pictured in a vaccination centre in Geneva, Switzerland, February 3, 2021. REUTERS/Denis Balibouse Read More Aug 9 (Reuters) - The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19. Moderna's (MRNA.O) vaccine may be best against Delta The mRNA vaccine from Pfizer
[Read more on Moderna’s Covid-19 vaccine.] The drugmaker Moderna announced on Monday that its coronavirus vaccine was 94.5 percent effective, joining Pfizer as a front-runner in the global race to contain a raging pandemic that has killed 1.2 million people worldwide. Both companies plan to apply within weeks to the Food and Drug Administration for emergency authorization to begin vaccinating the
[1/2] A sign marks the headquarters of the coronavirus disease (COVID-19) vaccine maker Moderna in Cambridge, Massachusetts, U.S., April 28, 2022. REUTERS/Brian Snyder CHICAGO, Dec 13 (Reuters) - An experimental cancer vaccine from Moderna Inc (MRNA.O) based on the messenger RNA (MRNA) technology used in successful COVID-19 vaccines has been shown to work against melanoma, sending Moderna shares m
Il bonus di bellezza dell’arte moderna in diversi mo(n)di Lasciati meravigliare dalla bellezza magnifica dell’arte con l’aiuto di RawRaw. Arte moderna, disegni a mano, giochi e bonus casino, e molto altro sta per comparire davanti ai tuoi occhi. L'arte moderna é sovrana nel mondo del casino online, che si ispira ai grandi capolavori del presente per offrire un bonus di esperienza di gioco e visiva
ModernawantstheFDAtoauthorizeitsCOVID-19vaccineforkidsunder6FacebookTwitterFlipboardEmailMarch23,202
A patient receiving a dose of the Moderna coronavirus vaccine during a trial in Washington State earlier this year.Credit...Ted S. Warren/Associated Press WASHINGTON — The coronavirus vaccine made by Moderna is highly protective, according to new data released on Tuesday, setting the stage for its emergency authorization this week by federal regulators and the start of its distribution across the
" data-check-event-based-preview="" data-is-vertical-video-embed="false" data-network-id="" data-publish-date="2020-11-16T12:40:58Z" data-video-section="business" data-canonical-url="https://www.cnn.com/videos/business/2020/11/16/moderna-coronavirus-vaccine-efficacy-cohen-newday-vpx.cnn" data-branding-key="" data-video-slug="moderna coronavirus vaccine efficacy cohen newday vpx" data-first-publish
Moderna COVID-19 Vaccine Update September 15th, 2021 Software Applications Storage DNA mRNA Protein Slide 2 Forward-looking statements and Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the Company’s development of the Moderna COVID-19 Vaccine (mRNA-1273); the a
Slide 1 Epstein-Barr virus (EBV) vaccine (mRNA-1189) Last program update: August 5, 2021 Program ID # Preclinical development Phase 1 Phase 2 Phase 3 Commercial Moderna rights COVID-19 vaccine mRNA-1273 mRNA-1273.351/-211 mRNA-1283 Worldwide BARDA funded Cytomegalovirus(CMV) vaccine mRNA-1647 Worldwide Zika vaccine mRNA-1893 Worldwide BARDA funded Flu vaccine mRNA-1010 mRNA-1020 mRNA-1030 Worldwid
j次のブックマーク
k前のブックマーク
lあとで読む
eコメント一覧を開く
oページを開く